Guardant Health Director Tariq Musa Sells 116 Shares at $59.02 on 2025-08-19

On August 19, 2025, Guardant Health, Inc. (GH) announced that Director Tariq Musa sold 116 shares at a price of $59.02 per share.

On August 19, 2025, Guardant Health, Inc. (GH) announced that Director Tariq Musa sold 116 shares at a price of $59.02 per share. This transaction was reported through a Form 4 filing, indicating a routine insider trading event. The sale comes amidst a series of equity awards and vesting events for new employees, reflecting the company's ongoing efforts to attract and retain talent in the precision oncology sector.

According to the Form 4 filing, Musa sold 116 shares, which were part of his restricted stock units (RSUs) that had vested and converted to common shares on August 15, 2025. The RSUs were part of a grant dated March 6, 2023, with a four-year vesting schedule. The transaction was executed at the market price of $59.02 per share, which is slightly above the exercise price of $41.42 per share set at the time of grant.

This sale is a standard, non-disclosable change in compensation-related equity and does not indicate a change in corporate control or a material shift in insider alignment. The transaction was reported in a timely manner, adhering to SEC regulations and maintaining transparency for investors.

Guardant Health continues to operate as a leading precision oncology company, focused on transforming patient care through advanced blood and tissue tests, real-world data, and AI analytics. The company's forward-looking statements emphasize the potential utilities and benefits of its liquid biopsy tests, which are subject to risks and uncertainties, as outlined in its annual reports and other filings.

References:
[1] https://www.biospace.com/press-releases/guardant-health-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-august-15-2025
[2] https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-8dd933c2f101.html